GREENVILLE, SC, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the transformational Z-pod topical delivery platform, announced that its scientific advisor, Adam Friedman MD, will serve as a keynote speaker at the Dermatology Update 2019 Fall Meeting in Toronto on November 7.

Dr. Adam Friedman, Professor and Interim Chair of Dermatology, Residency Program Director, Director of Translational Research, and Director of Supportive Oncodermatology at the George Washington School of Medicine and Health Sciences will lead the Stuart Maddin Lectureship during the Plenary Session I at 9:45am with the entitled lecture, “The Therapeutic Potential of Cannabinoids in Dermatology.”

Dr. Friedman commented: “I will review the biology of the endocannabinoid system as it relates to the skin and present state-of-the-art preclinical and clinical data on applications of cannabinoids for the treatment of inflammatory and neoplastic skin diseases such as acne, atopic dermatitis, psoriasis, dermatomyositis, and Cutaneous Lupus Erythematosus (CLE). I will also explain the well-understood solubility and penetration-related challenges of administering cannabinoids topically and present data from an animal model of lupus suggesting that Zylö’s delivery technology can overcome these challenges.”

Added Scott Pancoast, CEO of Zylö, “Dr. Friedman has been intimately involved in Zylö’s technology from the start. His leadership position in the dermatological field and his keynote speech lend credence to  Zylö’s commercialization initiatives designed to enhance the bioavailability of CBD and other cannabinoids through topical administration.  It also highlights the  market potential of our product suite. We look forward to Dr. Friedman’s keynote speech at the Dermatology Fall Update.”

About Zylö Therapeutics: Zylö has developed a breakthrough topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod technology platform has enabled the Patchless Patch concept and has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).

Scott R. Pancoast
CEO + Founder
(858) 775-6710
spancoast@zylotherapeutics.com